Drug Profile


Alternative Names: AGN-024; AGN-192024; Bimatoprost Sustained-Release Implant; BUDPF; Glash Vista Cutaneous Solution 0.03%; GlashVista; Latisse; Lumigan; Lumigan RC; LumiganX; preservative-free bimatoprost

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Allergan
  • Developer Allergan; Senju Pharmaceutical
  • Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Hypotrichosis; Ocular hypertension
  • Phase II Alopecia

Most Recent Events

  • 20 Dec 2016 Allergan initiates a phase III trial for Ocular hypertension and Glaucoma in Spain (Implant, Controlled-release) (EudraCT2015-003631-34)
  • 01 Oct 2016 Allergan completes a phase I trial for Alopecia in USA (Topical, Liquid) (NCT02848300)
  • 01 Jul 2016 Allergan initiates a phase I trial for Alopecia in USA (Topical, Liquid) (NCT02848300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top